Immunomodulatory effect of tonsil-derived mesenchymal stem cells in XXXX model of @entity2023 .

@entity1 @entity32 @entity26051 @entity18841 @entity2023 @entity146 @entity19 @entity639 @entity34493
BACKGROUND: Although several studies have claimed that mesenchymal stem cells (MSC) derived from @entity1 tissues can @entity32 , the immunomodulatory mechanism of MSCs remains unclear. OBJECTIVE: We aimed to determine the effects and the underlying mechanism of tonsil-derived MSCs (T-MSC) on @entity32 compared with adipose tissue- derived stem cells (ASC) in a @entity19 model of @entity2023 ( @entity2023 ). METHODS: MSCs were isolated from @entity1 palatine tonsil (T-MSC) and the surface markers were analyzed. The effect of T-MSCs was evaluated in 24 BALB/c @entity19 that were randomly divided into four groups (negative control group, positive control group, T-MSC group, and ASC group). MSCs were administered intravenously to ovalbumin (OVA) sensitized @entity19 (T-MSC and ASC groups) on days 18 to 23, and subsequent OVA challenge was conducted daily from days 24 to 28. Several parameters of @entity32 were assessed. RESULTS: T-MSC and ASC had similar characteristics in surface markers. Intravenous injection of T-MSC significantly @entity146 , eosinophil infiltration, serum total, and OVA-specific immunoglobulin E (IgE), and the nasal and systemic T-helper (Th) 2 cytokine profile. Further analysis revealed that nasal innate cytokines, such as interleukin (IL) 25 and @entity26051 , and chemokines, such as @entity639 , @entity34493 , induction was suppressed in T-MSCs injected groups, which explained their underlying mechanism. In addition, the T-MSC group had more inhibition of @entity32 than did the ASC group, which might be attributed to the more proliferative activity of T-MSC. CONCLUSION: Administration of T-MSC effectively @entity146 and inflammatory parameters in the @entity19 model of @entity2023 . T-MSC treatment reduced Th2 cytokines and OVA-specific IgE secretion from B cells. In addition, innate cytokine ( @entity18841 and @entity26051 ) expression and @entity639 messenger RNA expression was inhibited in the nasal mucosa, which is suggestive of the mechanism of @entity32 . Therefore, T-MSC treatment is potentially an alternative therapeutic modality in @entity2023 .
